Automated and combined HIV, HBV, HCV, and syphilis testing among illegal gold miners in French Guiana using a standardized dried blood device

Amandine PISONI[1], Elisa REYNAUD[2], Maylis DOUINE[3], Louise HUREAU[3], Carmen ALCOCER CORDELLAT[2], Roxane SCHAUB[3], Dennis POLAND[4], Richard MONKEL[4], Joan LOMMEN[4], Konstantin YENKOYAN[5], Stephen VREDEN[6], Mathieu NACHER[3], Edouard TUAILLON[1*]

1. Pathogenesis & Control of Chronic and Emerging Infections, Institut National de la Santé et de la Recherche Médicale (INSERM), U1058, Établissement Français du Sang (EFS), Montpellier University and Laboratory of Virology, Centre Hospitalier Universitaire de Montpellier, France.
2. Montpellier University Hospital, Montpellier, France.
3. Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Cayenne Hospital, Epidemiology of Tropical Parasitoses, EA 3593, Universite de Guyane, Cayenne, French Guiana.
4. Labonovum, Limmen, Netherlands.
5. Department of Biochemistry, Neuroscience Laboratory, Cobrain Center Yerevan State Medical University named after M. Heratsi, Yerevan, Armenia.
6. Foundation for Scientific Research of Suriname, Paramaribo, Suriname

***Corresponding author:** e-tuaillon@chu-montpellier.fr

Centre Hospitalier Universitaire de Montpellier, Laboratoire de Virologie Lapeyronie, 371 avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France. Tel : +33 4 67 33 83 40 Fax: +33 4 67 33 83 34

Abstract

Blood spotted onto filter paper can be easily collected outside healthcare facilities and shipped to a central laboratory for serological testing. However, dried blood testing generally requires manual processing for pre-analytical steps. In this study, we used a standardized blood collection device combined with an automated elution system to test illegal gold miners living in French Guiana for HIV, HBV, HCV and syphilis. We included 378 participants, 102 females and 266 males, in three illegal gold mining resting sites. Blood collected on the Ser-Col device (Labonovum) was eluted using an automated system (SCAUT Ser-Col automation, Blok System Supply) and an automated analyzer (Alinity i, Abbott). Ser-Col results were compared to both plasma results, considered the gold standard, and to DBS results, considered the reference sampling method using dried blood. In plasma samples, two participants (0.5%) tested positive for HIV, six (1.5%) tested positive for hepatitis B surface antigen (HBsAg), eight were weakly positive for anti-HCV antibodies but negative for HCV RNA, and 47 tested positive for treponemal antibodies (12.4%), including 20 females (19.6%) and 27 males (9.8%, p= 0.010179). We observed a full concordance of Ser-Col and DBS results for HIV diagnosis compared to plasma results. Ser-Col and DBS samples tested positive in five HBsAg carriers and negative for one participant with a low HBsAg level in plasma (0.5 IU/mL). All participants tested negative for HCV in Ser-Col and DBS samples, including the eight participants who tested low positive for HCV antibodies and HCV RNA negative in plasma. Among syphilis seropositive participants, 41 (87.2%) and 40 (85.1%) tested positive for treponemal antibodies in Ser-Col and DBS samples, respectively. The Ser-Col method allows automated dried blood testing of HIV, HBV, HCV and syphilis with performances comparable to DBS. Automated approaches to test capillary blood transported on dried blood devices may facilitate large-scale surveys and improve testing of populations living in remote areas.

Keywords: HIV, hepatitis B, hepatitis C, syphilis, vulnerable population, Dried Blood Spot

60 **Introduction**

61 Reducing the burden of infectious diseases requires a global approach that includes underprivileged
62 people. To date, a significant part of the world's population has insufficient access to reliable infectious
63 disease diagnostic services. Migration, forced displacement of populations, weak infrastructure and
64 long distance from health services are common unfavorable health factors. A lack of in vitro diagnostic
65 tools contributes largely to the mortality and morbidity induced by infectious diseases in resource-
66 limited countries (Organization, 2013). A low number of laboratories and poor logistical infrastructure
67 are major problems in many of these countries. Laboratory equipment defined by WHO as essential
68 for basic service readiness is also insufficient (Leslie et al., 2017). The weakness of human resources -
69 health professionals and biologists - should also be noted (Kruk et al., 2018).

70 Capillary blood sampling performed outside healthcare facilities is one strategy to improve the
71 screening of hard-to-reach and key populations. Dried blood spot (DBS) testing programs have been
72 implemented for several years, targeting intravenous drug users (McLeod et al., 2014), sex workers
73 (Shokoohi et al., 2016), homeless populations (Foroughi et al., 2017), migrants and men who have sex
74 with men (Bogowicz et al., 2016). Today, WHO considers DBS samples as a possible alternative to
75 serum/plasma to improve access to HIV, HBV and HCV screening and therapeutic monitoring.
76 However, DBS testing has several constraints, such as a lack of standardized blood sampling and elution
77 procedures and the need to manually process DBS cards, which have limited the use of DBS in clinical
78 laboratories.

79 In French Guiana, about 10,000 illegal gold miners, mainly Brazilians (95%), work on more than 700
80 different mining sites located in the primary forest (Douine et al., 2017). This neglected population
81 experiences very poor access to Health (Douine et al., 2017). People working on gold panning sites are
82 particularly exposed to vector-borne diseases, including malaria (Douine et al., 2016) and leishmaniasis
83 (Douine et al., 2017). Data also suggest a higher prevalence of sexually transmitted infections such as
84 HIV, hepatitis B (HBV) and syphilis than in other populations of French Guiana (Douine et al., 2019).

85 Transactional sex occurs frequently in gold mining sites (Douine et al., 2019; Gaillet et al., 2017).
86 According to a survey carried out in the city of Cayenne in French Guiana, it may contribute to 45% of
87 HIV cases in men and 10.7% in women (Nacher et al., 2010). In a study carried out on the gold sites of
88 French Guiana, about 10% of women declared having already engaged in sex work activity (Douine et
89 al., 2017).

90 In this study, we used an innovative blood collection device combined with an automated elution
91 system to test illegal gold miners living in French Guiana for HIV, HBV, HCV and syphilis.

92 **Material and Methods**

93 Study design

94 This study is part of the EU-funded "SCAUT" research project (from finger to laboratory: personalized
95 and automated blood collection for laboratory diagnostics). Participants were adults working in illegal
96 gold mining sites in French Guiana and included in the Malakit study. This study aimed to evaluate an
97 innovative malaria control strategy amongst gold miners working illegally in French Guiana.
98 Participants were included after having provided informed written consent. Testing for HIV, hepatitis
99 B virus (HBV), hepatitis C virus (HCV) and syphilis was offered at three resting sites located along the
100 border between French Guyana and Suriname, on the Maroni river: Albina, Grand Santi and
101 Maripasoula (Fig. 1). All participants had left a mining site less than seven days prior to being tested.
102 Samples collected from 1st October to 16th November were sent from the resting site to the hospital
103 center of Cayenne and then to the Montpellier University Hospital to be tested. Results from plasma
104 samples were communicated to collection sites within two weeks on each site during the post-test
105 counseling. Paired samples of Ser-Col and DBS were tested in parallel for the SCAUT study. The study
106 obtained approval from ethical committee in France: INSERM Ethics Evaluation Committee (No. 14-
107 187 of 09.12.2014), in Suriname: CMWO. Approval No: VG 25-17; ClinicalTrials.gov identifier (NCT
108 number: NCT03695770).

109 Sample processing

110 The processing of blood collected on the Ser-Col device (Labonovum, Netherlands) was performed
111 using an automated system (SCAUT Ser-Col automation, Blok System Supply, Netherlands). The Ser-
112 Col device contains a microfluidic paper separating plasma from whole blood. The automated system
113 performed the elution from dried plasma contained in one centimeter of paper in 100µL of Ser-Col
114 buffer.

115 Blood were spotted onto Whatman 903™ Protein Saver Cards (Whatman GmbH, Dassel, Germany)
116 Elution were manual. One punch of 6 mm in diameter was eluted in 100µL of phosphate-buffered
117 saline.

118 Biological analysis

119 HIV p24/antibodies, HBsAg, anti-HCV antibodies, and anti-treponemal antibodies were assessed using
120 fully automated chemiluminescence immunoassays (Alinity i, Abbott, IL, USA). Samples that tested
121 positive for HIV were confirmed using a rapid confirmatory assay based on immune-chromatography
122 and automated reading (Geenius™ HIV1/2 Confirmatory Assay, Bio-Rad, France). Plasma samples
123 positive for anti-treponemal antibodies were tested by Rapid Plasma Reagin Assays (ASI RPR, Arlington
124 Scientific Inc.). All assays were done in accordance with the manufacturer's instructions.

125 Data analysis and statistical methods

126 The HIV, HBV, HCV and syphilis status of participants was established by testing plasma samples. Ser-
127 Col results were compared to plasma results, considered the gold standard for diagnostic testing in
128 general, and to DBS results, considered the reference sampling method using dried blood. The Chi-
129 square test was used to compare percentages. Receiver operating characteristic curves (ROCs) were
130 used to identify the positive threshold of anti-treponemal antibodies in Ser-Col and DBS. Spearman's
131 non-parametric test was used to assess the correlation between results of anti-treponemal antibodies
132 in Ser-Col and DBS, versus plasma. Data results were analyzed using GraphPad Prism 9.3.1 (GraphPad
133 Prism Software Inc.).

134 **Results**

135 We included 378 participants, 276 males and 102 females, in three illegal gold mining resting sites. The
136 median (IQR) age of the participants was 39 years (31-48).

137 We first tested participants for HIV, HBV, HCV and syphilis infections using plasma to determine their
138 infection status for these infections (Fig.1 and Table 1). Two participants tested positive for HIV. HIV
139 infection was confirmed with the Geenius test. The pattern of antibodies showed IgG directed against
140 gp160, gp41, p24 and p31 (low signal) of HIV-1 for the first participant, and gp160, gp41, and p24 with
141 no p31 antibodies for the second one. We did not observe any reactivity for HIV-2 antigens (gp140,
142 gp36). Six participants had HBV infection demonstrated by the presence of HBsAg. One participant had
143 a weakly positive result with a signal-to-cut-off ratio (S/CO) of less than 10, corresponding to an HBsAg
144 concentration of 0.5 IU/mL. Eight participants tested positive for anti-HCV antibodies, but all had index
145 values close to the threshold of positivity. In addition, all of them tested negative for HCV RNA,
146 suggesting a recovered hepatitis C infection or a false-positive result. 47 participants tested positive
147 for syphilis using the treponemal test, (S/CO: 1.03 to 19.59). The rate of positivity for treponemal
148 antibodies was higher in females than in males: 20/102 (19.6%) versus 27/276 (9.8%, p= 0.01),
149 respectively. Among participants who tested positive for treponemal antibodies, 13 (27.6%) also tested
150 positive using the non-treponemal test, suggesting an active stage of infection or a recently treated
151 infection (3 females, 10 males). RPR dilution titers were 1:2 for five participants, 1:4 for six, 1:8 for one,
152 and 1:32 for one.

153 The Ser-Col samples then were tested for HIV, HBV, HCV and syphilis after automated elution. The
154 eluates were assessed directly on the Abbott system without transfer into a secondary tube. All of the
155 Ser-Col samples from HIV-seronegative participants tested negative, leading to a specificity of 100%.
156 Two participants diagnosed with HIV infection were found positive using the Ser-Col device. The HIV
157 confirmatory test was positive in the two samples. We observed a partial agreement between Ser-Col
158 and plasma in one sample in whom the p31 band was detected in plasma but not in Ser-Col eluate

159 (Table 1). Seven of the eight HBsAg carriers tested positive when using the Ser-Col device. The Ser-Col
160 sample with the lowest HBsAg concentration in the paired plasma sample (0.5 IU/mL) tested negative.
161 Two Ser-Col samples from HBsAg negative participants had signals above the cut-off and were
162 considered false-positive. The S/CO were close to the positive threshold. All HCV seronegative
163 participants were also found negative for anti-HCV antibodies using the Ser-Col device. The eight
164 participants with the HCV Abs +/RNA- pattern were found negative using the Ser-Col device. All Ser-
165 Col samples from participants seronegative for anti-treponemal antibodies in plasma tested negative.
166 20 out of 47 (42.5%) participants who tested positive for anti-treponemal antibodies in plasma had
167 S/CO results below the threshold of the manufacturer. The signal on the cut-off index was significantly
168 higher in participants who tested positive for anti-treponemal antibodies in the plasma. We
169 established an optimized positive threshold based on a ROC curve. The best compromise was reached
170 with an S/CO threshold of 0.28 instead of 1, corresponding to a sensitivity and a specificity of 74.6%
171 and 98.4%, respectively. The AUC was 95.17 with this new threshold.
172
173 Finally, DBS samples were tested for HIV, HBV, HCV and syphilis. We observed identical screening
174 results for HIV using DBS compared to plasma samples. The p31 band bands were also missing on the
175 DBS samples of the first and second HIV positive participants (Table 1). As for the Ser-Col samples, the
176 sample with the lowest HBsAg concentration tested negative using DBS. Two DBS samples collected
177 from HBsAg negative participants had an S/CO above the positive threshold. These samples were not
178 the same as those found false-positive using the Ser-Col samples. 23 out of 47 (48.9%) participants
179 who tested positive for anti-treponemal antibodies in plasma had S/CO results below the threshold of
180 the manufacturer. The ROC curve for the screening of anti-syphilis antibodies led to an AUC of 95.25,
181 with a sensitivity and a specificity of 73.9% and 98.1%, respectively, with a threshold of 0.28.
182
183

184 **Discussion**

185 Our study shows the feasibility of serological screening for sexually transmitted infections in a
186 vulnerable population living in a remote area using a standardized dried blood device and a fully
187 automated processing system. The clinical performance of the assays using the Ser-Col device
188 appeared as good as those using DBS while overcoming some of the limitations related to DBS
189 processing. This approach allows combined screening for HIV, HCV, HBV and syphilis infections on
190 blood collected outside health care facilities in gold mining resting sites.

191 French Guiana has the highest prevalence of HIV and HBV among French regions (Moana et al., 2016;
192 Nacher et al., 2018). The HIV, HBV, HCV and syphilis prevalences observed in our study are consistent
193 with those previously reported in this population (Douine et al., 2019). With the exception of syphilis,
194 the number of positive cases was relatively low, which leads to imprecise estimates of prevalence.
195 These figures are close to HIV, HBV and HCV prevalence estimations in French Guiana. The prevalence
196 of HIV has been estimated at 1.5% (Nacher et al., 2018), HBV 2.96% and HCV infection 0.67% (Moana
197 et al., 2016). In remote areas and among vulnerable populations, some people living with HIV and viral
198 hepatitis are unaware of their infection status (Organization, 2016). It is of primary importance to
199 increase the frequency of screening for HIV, HBV and HCV infections. Capillary blood sampling and
200 dried blood transportation could facilitate large-scale health surveys. This type of population testing
201 has been carried out using DBS, for example for viral hepatitis (Meda et al., 2018) and SARS-CoV-2
202 (Warszawski et al., 2022).

203 This field study was carried out on difficult terrain. The population of illegal gold miners in French
204 Guiana consists of migrants living far from transport networks and health infrastructure in a harsh
205 tropical environment. In this study, sampling was done close to the field and in vitro diagnoses were
206 performed in a central laboratory certified ISO 15189 for HIV, HBV, HCV and syphilis testing using a
207 high-throughput serological platform. The transportation of samples from the field to a central
208 laboratory is facilitated when using dried blood because there is no risk of the biological fluid spilling

209 and no risk of virus transmission. Serological and molecular tests on DBS have shown satisfactory
210 analytical performance for HIV and viral hepatitis (Lange et al., 2017a; Lange et al., 2017b). DBS is
211 recommended by WHO for the diagnosis of HIV and viral hepatitis B and C to improve access to in vitro
212 diagnosis of populations with poor access to plasma tests (Organization, 2017; World Health et al.,
213 2014). Nevertheless, DBS suffers from significant limitations that hamper its use, including the lack of
214 standardization of the sample and the absence of automation for the pre-analytical steps: punching,
215 transfer and elution. The manual processing of DBS is a source of error and limits its integration in
216 medical laboratories. The Ser-Col device and its automated processing overcome these limitations.

217 In our study, the screening on Ser-Col samples presented a high specificity, identifying HIV and HBV
218 infections with the exception of one weakly HBsAg-positive sample. Two Ser-Col samples were false-
219 positive for HBsAg but with low S/CO values. The specificity for HCV also appeared high but the
220 sensitivity could not be calculated since all participants tested seronegative for HCV RNA. The
221 performance of the syphilis assay is more uncertain since about a quarter of the low plasma positive
222 participants were not detected when using the Ser-Col device. These participants had relatively weak
223 positive results in plasma, suggesting an old, cured syphilis. However, a very recent infection would
224 also be possible. Performance for syphilis screening was similar using the Ser-Col device and DBS. Even
225 if the performance of screening for anti-treponemal antibodies on Ser-Col or DBS is lower than that of
226 plasma, this method of blood sampling could be useful for syphilis testing in the field. A trade-off
227 between the analytical performances of the test and its accessibility in the field should be considered
228 to evaluate the benefit of in vitro diagnosis methods in the real world, as emphasized in the WHO
229 guidelines (Organization, 2017; World Health et al., 2014).

230 Our study has several limitations. First, we did not evaluate loss of follow-up before participants
231 obtained the results. This is an important aspect of screening strategies. Compared to POC tests,
232 laboratory analyses, whether carried out on plasma or dried blood samples, entail a longer delay
233 before the result is returned, and therefore a greater risk of patient loss to follow-up before the test

234 results are given to the patient (Bottero et al., 2015). Another limitation is the low number of positive
235 participants for HIV, HBV and HCV infections even though a large number of participants were tested.
236 Finally, we only performed qualitative tests, whereas quantitative results may be interesting for the
237 diagnosis of infectious diseases.

238 **In conclusion**, the Ser-Col device combined with automated elution allows the standardization and
239 safety of the pre-analytical steps of analysis performed on dried blood samples. The clinical
240 performances of the assays using the automated Ser-Col method appeared as good as those obtained
241 with the DBS samples processed manually. Automated approaches to test capillary blood transported
242 on dried blood devices are needed to enable testing of vulnerable populations living outside healthcare
243 facilities and facilitate large-scale surveys assessing the burden of different infectious pathogens.

244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262

Declarations

Ethics approval and consent to participate

The study obtained approval from ethical committee in France: INSERM Ethics Evaluation Committee (No. 14-187 of 09.12.2014), in Suriname: CMWO. Approval No: VG 25-17; ClinicalTrials.gov identifier (NCT number: NCT03695770).

Competing interests

DP, RM and JL are Labonovum employees.

Funding

This study is part of the EU-funded “SCAUT” research project (from finger to laboratory: personalized and automated blood collection for laboratory diagnostics).

Acknowledgements

The authors would like to thank all participants for participating in this study.

CRediT authorship contribution statement

Amandine PISONI : Conceptualization, Methodology, Validation, Formal analysis, Writing - Original Draft ; **Elisa REYNAUD** : Validation ; **Maylis DOUINE** : Investigation ; **Louise HUREAU** : Investigation ; **Carmen ALCOCER CORDELLAT** : Investigation ; **Roxane SCHAUB** : Investigation ; **Dennis POLAND** : Conceptualization and Methodology ; Funding acquisition ; **Richard MONKEL** : Investigation : Resources ; **Joan LOMMEN** : Investigation ; **Konstantin YENKOYAN** : Conceptualization and Methodology ; Funding acquisition ; **Stephen VREDEN** : Writing - Review & Editing ; **Mathieu NACHER**: Investigation, Resources ; **Edouard TUAILLON** : Conceptualization and Methodology; Formal analysis: Resources ; Writing - Original Draft; Funding acquisition ; **All authors** : Writing - Review & Editing

References:

Bogowicz, P., Moore, D., Kanters, S., Michelow, W., Robert, W., Hogg, R., Gustafson, R., Gilbert, M., 2016. HIV testing behaviour and use of risk reduction strategies by HIV risk category among MSM in Vancouver. International journal of STD & AIDS 27, 281-287.

Bottero, J., Boyd, A., Gozlan, J., Carrat, F., Nau, J., Pauti, M.D., Rougier, H., Girard, P.M., Lacombe, K., 2015. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open forum infectious diseases 2, ofv162.

Douine, M., Mosnier, E., Le Hingrat, Q., Charpentier, C., Corlin, F., Hureau, L., Adenis, A., Lazrek, Y., Niemetsky, F., Aucouturier, A.L., Demar, M., Musset, L., Nacher, M., 2017. Illegal gold miners in French Guiana: a neglected population with poor health. BMC public health 18, 23.

Douine, M., Musset, L., Corlin, F., Pelleau, S., Pasquier, J., Mutricy, L., Adenis, A., Djossou, F., Brousse, P., Perotti, F., Hiwat, H., Vreden, S., Demar, M., Nacher, M., 2016. Prevalence of Plasmodium spp. in illegal gold miners in French Guiana in 2015: a hidden but critical malaria reservoir. Malaria journal 15, 315.

Douine, M., Schaub, R., Jardin, H., Adenis, A., Nacher, M., Hureau-Mutricy, L., Vreden, S., Mosnier, E., Pisoni, A., Tuaillon, E., 2019. High prevalence of hepatitis B and syphilis in illegal gold miners in French Guiana. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 25, 1051-1053.

Foroughi, M., Moayedi-Nia, S., Shoghli, A., Bayanolhagh, S., Sedaghat, A., Mohajeri, M., Mousavinasab, S.N., Mohraz, M., 2017. Prevalence of HIV, HBV and HCV among street and labour children in Tehran, Iran. Sexually transmitted infections 93, 421-423.

Gaillet, M., Brousse, P., Guarmit, B., Adriouch, L., Schaub, R., Naldjinan-Kodbaye, R., Carrera, C., Lormée, N., Simon, T., Aubry, Y., Epelboin, L., Martin, E., Bidaud, B., Niemetzky, F., Djossou, F., Mosnier, E., 2017. Hépatites virales B - Delta et C dans les centres délocalisés de prévention et de soins (CPDS) de Guyane française. Bulletin de Veille Sanitaire - Cire Antilles Guyane, 23-28.

Kruk, M.E., Gage, A.D., Arsenault, C., Jordan, K., Leslie, H.H., Roder-DeWan, S., Adeyi, O., Barker, P., Daelmans, B., Doubova, S.V., English, M., García-Elorrio, E., Guanais, F., Gureje, O., Hirschhorn, L.R., Jiang, L., Kelley, E., Lemango, E.T., Liljestrand, J., Malata, A., Marchant, T., Matsoso, M.P., Meara, J.G., Mohanan, M., Ndiaye, Y., Norheim, O.F., Reddy, K.S., Rowe, A.K., Salomon, J.A., Thapa, G., Twum-Danso, N.A.Y., Pate, M., 2018. High-quality health systems in the Sustainable Development Goals era: time for a revolution. The Lancet. Global health 6, e1196-e1252.

Lange, B., Cohn, J., Roberts, T., Camp, J., Chauffour, J., Gummadi, N., Ishizaki, A., Nagarathnam, A., Tuaillon, E., van de Perre, P., Pichler, C., Easterbrook, P., Denkinger, C.M., 2017a. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses. BMC infectious diseases 17, 700.

Lange, B., Roberts, T., Cohn, J., Greenman, J., Camp, J., Ishizaki, A., Messac, L., Tuaillon, E., van de Perre, P., Pichler, C., Denkinger, C.M., Easterbrook, P., 2017b. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC infectious diseases 17, 693.

Leslie, H.H., Spiegelman, D., Zhou, X., Kruk, M.E., 2017. Service readiness of health facilities in Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United Republic of Tanzania. Bulletin of the World Health Organization 95, 738-748.

McLeod, A., Weir, A., Aitken, C., Gunson, R., Templeton, K., Molyneaux, P., McIntyre, P., McDonald, S., Goldberg, D., Hutchinson, S., 2014. Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. Journal of epidemiology and community health 68, 1182-1188.

Meda, N., Tuaillon, E., Kania, D., Tiendrebeogo, A., Pisoni, A., Zida, S., Bollore, K., Medah, I., Laureillard, D., Moles, J.P., Nagot, N., Nebie, K.Y., Van de Perre, P., Dujols, P., 2018. Hepatitis B and C virus

seroprevalence, Burkina Faso: a cross-sectional study. Bulletin of the World Health Organization 96, 750-759.

Moana, G.-S., Pierre, M., Richard, N., Marie-Josée, L., Sandrine, P.-F., Laurent, C., André, C., 2016. Tour d'horizon sur les hépatites chroniques B et C dans les départements-régions d'Outre-Mer et collectivités territoriales uniques. Hépato-Gastro & Oncologie Digestive 23, 984-991.

Nacher, M., Adriouch, L., Huber, F., Vantilcke, V., Djossou, F., Elenga, N., Adenis, A., Couppié, P., 2018. Modeling of the HIV epidemic and continuum of care in French Guiana. PloS one 13, e0197990.

Nacher, M., Vantilcke, V., Parriault, M.C., Van Melle, A., Hanf, M., Labadie, G., Romeo, M., Adriouch, L., Carles, G., Couppié, P., 2010. What is driving the HIV epidemic in French Guiana? International journal of STD & AIDS 21, 359-361.

Organization, W.H., 2013. A Universal Truth: No Health Without a Workforce. World Health Organization, Geneva.

Organization, W.H., 2016. GLOBAL HEALTH SECTOR STRATEGY ON HIV 2016–2021TOWARDS ENDING AIDS. World Health Organization, Geneva.

Organization, W.H., 2017. Guidelines on hepatitis B and C testing. World Health Organization, Geneva.

Shokoohi, M., Karamouzian, M., Khajekazemi, R., Osooli, M., Sharifi, H., Haghdoost, A.A., Kamali, K., Mirzazadeh, A., 2016. Correlates of HIV Testing among Female Sex Workers in Iran: Findings of a National Bio-Behavioural Surveillance Survey. PloS one 11, e0147587.

Warszawski, J., Beaumont, A.L., Seng, R., de Lamballerie, X., Rahib, D., Lydié, N., Slama, R., Durrleman, S., Raynaud, P., Sillard, P., Beck, F., Meyer, L., Bajos, N., 2022. Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort. BMC infectious diseases 22, 41.

World Health, O., Centers for Disease, C., Prevention, United States. Agency for International, D., Global Fund to Fight Aids, T., Malaria, African Society for Laboratory, M., 2014. Technical and operational considerations for implementing HIV viral load testing: interim technical update. World Health Organization, Geneva.

Figure 1.



Figure 1. Sampling location of the Orpal study in French Guiana. Green area indicates illegal gold mining sites. Orange circles on the Maroni river indicate collection sites that were located in resting places.

Figure 2.



Figure 2. Screening of infections in illegal gold miners in French Guyana. A) Results for HIV, hepatitis B, hepatitis C, and syphilis in plasma samples HBsAg: hepatitis B surface antigen; Abs: antibodies; RPR: rapid plasma reagin test. B) Individual results.

Figure 3.



Figure 3. Results of HIV, hepatitis B and hepatitis C testing on Ser-Col and DBS samples. A) Results of HIV testing in Ser-Col samples and dried blood spot (DBS) according to HIV status in sera. B) Results of HBsAg testing in Ser-Col samples and dried blood spot (DBS) according to HBsAg status in sera. C) Results of hepatitis C antibody testing in Ser-Col samples and dried blood spot (DBS) according to anti-HCV status in sera. All samples tested positive for anti-HCV Abs were negative for HCV RNA.

Figure 4.



Figure 4. Anti-treponemal antibody results in Ser-Col and Dried Blood Spot samples. A) Anti-treponemal antibodies in Ser-Col samples and dried blood spot (DBS) according to syphilis serological status in plasma; dotted line: threshold of the manufactuer; solid line: optimized threshold for Ser-Col and DBS samples. B) Receiver operating characteristic curve (ROC) evaluating anti-treponemal antibody detection in Ser-Col samples. C) ROC evaluating anti-treponemal antibody detection in DBS samples.

Table 1. Serological results using plasma, Ser-Col, and DBS samples.

	Plasma (n=378)		Ser-Col (n=378)		DBS (n=378)	
	Negative	Positive	Negative	Positive	Negative	Positive
HIV						
HIV-Abs/p24 Ag	376	2	376	2	376	2
Confirmatory assay[µ]		gp160+, gp41+, p31+, p24+ gp160+, gp41+, p31-, p24+		gp160+, gp41+, p31-, p24+ gp160+, gp41+, p31-, p24+		HIV-1: gp160+, gp41+, p31-, p24+ HIV-1: gp160+, gp41+, p31-, p24+
Hepatitis B						
HBsAg	372	6	373	5	373	5
Hepatitis C						
HCV Abs	370	8	378	0	378	0
HCV RNA[µ]	8	0	ND	ND	ND	ND
Syphilis						
Treponemal Abs	331	47	337	41	338	40
Non-treponemal test[µ]	34	13				
1:2		5	ND	ND	ND	ND
1:4		6	ND	ND	ND	ND
1:8		1	ND	ND	ND	ND
1:32		1	ND	ND	ND	ND

Abs : antibodies ; Ag : antigen ; HBsAg : Hepatitis B surface antigen ; ND : not done. [µ] among seropositive samples.

Graphical abstract

Automated and combined HIV, HBV, HCV, and syphilis testing among illegal gold miners in French Guiana using a standardized dried blood device